From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

Key Takeaways

• AI-designed regulatory DNA could make production cell lines more programmable and reduce reliance on large clone screens.

• Targeted integration and epigenomically informed locus selection can improve control over transgene expression and stability.

• Multiplex CHO cell engineering is expanding optimization beyond titer to include metabolism, impurity burden, survival, and product quality.

• Synthetic gene circuits may enable future cell lines to sense production stress and adjust their own behavior dynamically.

• Fully AI-designed production cell lines do not yet exist, but design–build–test–learn workflows are moving the field toward more rational, data-driven development.

Cell line development has long depended on finding exceptional performers within a broad and often heterogeneous population. Following transgene introduction, selection, cloning, expansion, and early productivity testing, developers must identify candidates that can sustain acceptable growth, expression, product quality, and stability over prolonged culture. Random integration and gene amplification can produce clones with markedly different phenotypes, even when they originate from the same parental host and carry the same expression construct. That variability creates opportunity, but it also makes cell line development a time- and labor-intensive search process.

The industry has already introduced automation, high-throughput analytics, site-specific integration, and increasingly sophisticated statistical tools into this workflow. Machine learning (ML) is also beginning to support earlier discrimination among cell lines. Label-free multimodal imaging combined with ML classification has distinguished among monoclonal antibody (mAb)-producing Chinese hamster ovary (CHO) lines at early passages, showing that phenotypic information can be extracted before conventional long-term assessments are complete.¹

These advances do not amount to artificial intelligence (AI)-designed cell lines. Most current applications of AI in cell line development remain closer to classification, prediction, and candidate ranking than to prospective biological design. The more important emerging shift is that developers are beginning to define more of the search space before screening begins. Instead of accepting the expression cassette, genomic location, host genotype, cellular stress response, and product-quality machinery as loosely controlled or independent variables, they can increasingly treat each as a design choice.

Screening will remain essential because production phenotypes emerge from interactions among many cellular systems. A more design-oriented workflow could nevertheless reduce the number of poorly informed candidates entering that screen. The future objective is not to eliminate empirical validation but to build smaller and more purposeful sets of cell lines whose differences reflect deliberate biological hypotheses.

A production cell is not defined by a single expression cassette. Its performance reflects the combined effects of coding sequence, promoter and enhancer architecture, untranslated regions, gene ratios, copy number, integration site, chromatin environment, host genotype, metabolism, secretion capacity, stress response, apoptosis, glycosylation machinery, and culture conditions. Each layer adds possible design choices, and the number of potential combinations quickly exceeds what can be tested exhaustively.

That combinatorial problem creates a natural role for computational methods. Sequence models can learn relationships between regulatory DNA and expression. Systems models can nominate metabolic or signaling targets. Machine learning can identify phenotypic patterns that distinguish more promising candidates. Active learning can select the next experiment expected to provide the greatest information or improvement, incorporate the result, retrain the model, and repeat the cycle. Active-learning frameworks have already been applied to regulatory-DNA optimization in non-CHO systems, demonstrating how iterative experimentation can explore a large sequence space more efficiently than uniform testing.^2,3

No verified study has yet connected all of these layers into one integrated design engine for industrial CHO cell lines. The available evidence instead shows separate capabilities at different levels of maturity. Regulatory sequences can be designed computationally. Genomic integration can be directed to selected loci. Host pathways can be modified through multiplex genome engineering. Cellular stress can be monitored and, in some cases, coupled to feedback-responsive circuits. Glycosylation can be altered through defined changes to the host genotype. ML can help classify existing production candidates.

The central opportunity lies in linking these elements through a common design–build–test–learn framework. A model could propose a set of expression architectures or host edits, experimental data could reveal how those designs behave, and the next round could focus on the combinations most likely to improve the desired phenotype. This would make cell line development progressively more learnable, even if the underlying biology never becomes completely predictable.

Regulatory DNA represents one of the most computationally advanced layers of the emerging design space. Deep-learning models trained on large functional data sets have generated synthetic cis-regulatory elements with programmed activity profiles. In one study, the model learned from measured regulatory output across 776,474 DNA sequences and was then used to design synthetic elements for specified cell-type activity.⁴

This work demonstrates that regulatory DNA can be treated as an engineering substrate rather than solely as a collection of naturally occurring elements from which developers select. It does not demonstrate that industrial CHO promoters can already be generated on demand for stable therapeutic-protein production. The experimental context matters, and regulatory elements that perform well in one cell type, assay format, or genomic environment may not behave identically after stable integration into a production host.

A related regulatory design framework has been tested in CHO-K1 cells. The system used a synthetic upstream regulatory architecture developed through large-scale sequence testing and computational analysis, providing evidence that algorithmically informed regulatory design can function in a production-relevant mammalian host.⁵ The study did not establish an end-to-end commercial cell line platform, but it narrows the distance between sequence-design research and CHO expression-system engineering.

Untranslated regions offer another potential design layer. Deep learning has been used to create 5′ untranslated regions that improved translation in mammalian mRNA applications. The resulting sequences were evaluated with mRNAs encoding gene-editing enzymes across two targets and two cell lines.⁶ That application differs substantially from stable recombinant-protein production, but it shows that transcript architecture can also be optimized through sequence-to-function models.

Active learning could make this process more efficient by selecting which regulatory sequences should be built and tested next. The verified evidence for active-learning optimization of regulatory DNA comes from systems outside industrial CHO production, so its use in stable production-cell development remains prospective.^2,3 Even so, the method addresses a practical constraint: stable-cell experiments are too expensive and slow for indiscriminate exploration of every promoter, enhancer, untranslated region, insulator, and gene-ratio combination.

The expression program also depends on where it operates. Genomic context can influence transcriptional activity, silencing, and long-term stability. Histone-modification and expression data have been used to identify candidate CHO genomic regions for targeted integration. Three sites were tested using reporter-expressing cell pools, and selected regions produced higher expression and greater stability than random integration under the conditions studied.⁷

Those results support epigenomically informed integration-site selection, but they should not be mistaken for AI prediction of an optimal production locus. The study used reporter-expressing heterogeneous pools rather than commercial mAb-producing clones, and the reported performance cannot be generalized without further validation.⁷

Landing-pad systems provide a more direct means of controlling genomic placement. Bxb1 integrase has been used to introduce genetic payloads into predetermined CHO loci, and engineering of the integrase improved stable integration efficiency.8 By fixing the genomic location, developers can compare expression constructs under more controlled conditions and reduce variability associated with uncontrolled integration. Targeted placement does not remove the need to evaluate clone behavior, but it converts one major source of uncertainty into a defined platform parameter.

The next step beyond expression-cassette design is to treat the host cell itself as an engineered manufacturing chassis. Multiplex genome editing has already shown that CHO hosts can be redesigned around objectives extending beyond recombinant-protein titer.

One study created CHO clones carrying six, 11, and 14 host cell–protein knockouts. The engineered lines showed reductions of 40–70% in total host cell–protein content, and selected clones also displayed favorable growth or productivity characteristics. Lower impurity burden facilitated downstream purification of a mAb.⁹ This work is important because it expands the design target from how much product the cell makes to how cleanly and efficiently that product can be recovered.

A future host-design objective could therefore encompass productivity, growth, impurity burden, downstream processability, product quality, and stability. Evidence showing that all of these attributes can be optimized simultaneously has yet to be published, but it has been established that the host genome can be deliberately altered to influence several manufacturing outcomes.

RNA-level engineering provides another route to rapid and potentially reversible perturbation. CRISPR-Cas13d has been used in CHO-K1, DG44, and DUXB11 cells to knock down genes associated with apoptosis, metabolism, gene amplification, and glycosylation. Knockdown efficiencies of 60–80% were reported for targets including GS, BAK, BAX, PDK1, and FUT8.¹⁰ The study demonstrates a versatile tool for probing multiple host pathways, although it does not show that those pathways were optimized together in one stable production line.

Metabolic engineering offers a more model-driven example. A reconstructed CHO metabolic network and transcriptional data associated with antibody production were used to identify candidate genes in amino-acid catabolism. CRISPR-Cas9 was then applied to nine genes across seven pathways. Disruption of selected targets increased growth-related measures and reduced lactate or ammonium production under the tested conditions.¹¹

This model-to-edit workflow illustrates how production-cell engineering may increasingly begin with a desired phenotype rather than a convenient genetic target. The model narrows the candidate set, targeted editing tests the hypothesis, and the resulting data can improve subsequent decisions. The process is still empirical, but it is more purposeful than screening undirected genetic variation.

Apoptosis pathways are also experimentally accessible. Gene knockdown and knockout studies have targeted cell-death regulators in CHO cells, including BAK and BAX through Cas13d-based perturbation.¹⁰ These interventions support the broader concept of designing survival characteristics, but current evidence does not establish a computationally optimized program that balances apoptosis resistance with productivity, growth, product quality, and long-term stability.

Protein production places demands on cellular folding, processing, and secretion systems. When those demands exceed capacity, the resulting proteotoxic stress can activate the unfolded protein response (UPR), alter translation, reduce viability, and constrain productivity. The ability to measure and respond to that burden creates a path toward dynamic cell-line control.

An endogenous CHO reporter has been developed by inserting a fluorescent readout into the HSPA5 locus, which encodes the endoplasmic reticulum chaperone BiP. The reporter responded to chemically induced stress and changed during batch culture. Antibody-producing lines were also generated in the reporter background, and reporter fluorescence correlated with productivity among targeted integrants.¹²

This approach makes an otherwise hidden cellular state visible during cell line evaluation. Rather than relying only on final titer or viability measurements, developers can monitor a biological signal associated with the cell’s capacity to handle recombinant protein production. Such reporters could help distinguish lines that achieve high expression through sustainable cellular adaptation from those operating close to a damaging stress threshold.

Feedback-responsive cell factories extend the concept from sensing to action. Synthetic circuits have been engineered to detect proteotoxic stress and modulate branches of the UPR in response. The systems were evaluated with tissue plasminogen activator and the bispecific antibody blinatumomab, demonstrating that stress-responsive regulation can be applied to more than one therapeutic-protein format.¹³

Dynamic regulation differs from constitutive host engineering. A cell that continuously overexpresses a chaperone or suppresses a stress pathway may incur unnecessary metabolic burden when that intervention is not needed. A feedback circuit can activate or attenuate a response as the intracellular state changes. This creates the possibility of balancing productivity with cellular health rather than maximizing one variable continuously.

Current systems remain far from autonomous manufacturing control. No verified study has demonstrated a single circuit that jointly regulates stress, apoptosis, metabolism, glycosylation, and productivity in a commercial CHO process. Direct links between process analytical technology signals and biological actuators that continuously adjust critical quality attributes also remain limited.¹⁴ The significance of the present work lies in showing that production cells can sense internal conditions and change their behavior accordingly.

A production host does more than generate protein mass. It also influences glycosylation, folding, assembly, charge variants, impurity profiles, and other characteristics that can affect product performance. Glycoengineering provides some of the clearest evidence that host-cell design can target product quality directly.

For recombinant lysosomal enzymes, researchers created a panel of engineered CHO lines intended to generate different glycan structures and evaluated those configurations within a defined glycosylation design space. The work explored glycan features relevant to cellular uptake, biodistribution, and circulation.¹⁵ This was not simply a search for the highest-producing clone. The host genotype was varied to create distinct product attributes, and the resulting glycoforms were tested against a therapeutic objective.

Other studies have shown that defined-site integration and coordinated expression of multiple glycosylation enzymes can alter mAb glycan profiles and effector functions. Panels of glycosylation mutants have also connected specific host modifications with product glycan outcomes, while product-directed engineering has been used to make CHO-derived antibodies more similar to reference products produced in murine cell lines. These examples show that the host can be configured around a target quality profile rather than treated as a fixed background.

The relationship between genotype and product quality remains context dependent. The same edit may produce different effects across parental hosts, products, culture conditions, or integration architectures. An algorithm cannot yet guarantee a specified glycan distribution from a proposed set of edits. Even so, glycoengineering demonstrates a key principle: the cell line can become part of product design.

That principle raises a broader question about molecule fit. Different proteins may impose different demands on folding, assembly, secretion, redox balance, proteolysis control, metabolism, and glycosylation. Stress-responsive circuits have already been tested with distinct therapeutic-protein formats, and promoter, metabolic, secretome, and glycosylation engineering can all be adjusted independently.^5,9,11,13,15

A future platform might therefore comprise a family of characterized chassis rather than one universal parental line. One host could emphasize secretory capacity, another could support complex multisubunit assembly, another could provide a specified glycan profile, and another could minimize particular host-cell proteins or proteases. No verified source shows that AI currently designs these modality-specific host families. The concept remains a plausible extension of capabilities that have so far been demonstrated separately.

The increasing programmability of production cells does not make their behavior fully predictable. Regulatory sequences can perform differently across cell types, genomic loci, and assay formats. A construct that works well in a transient reporter system may behave differently after stable integration, prolonged culture, adaptation, and scale-up.^4,6,7

Multiple edits also create epistatic effects. A promoter that raises transcription may increase stress. A metabolic edit that improves growth may alter product quality or nutrient demand. An apoptosis-resistant line may survive longer without maintaining the desired specific productivity. A glycosylation edit may affect both the intended glycan structure and other aspects of cell physiology. Individually beneficial interventions may not remain beneficial when combined.

Genotype-to-phenotype models remain incomplete. Omics data sets can reveal associations, and metabolic models can prioritize targets, but neither can yet predict all the causal interactions that determine stable productivity and product quality. Long-term stability presents a particular challenge because molecular changes accumulated during extended passaging may alter metabolism, expression, or production performance in ways that are difficult to anticipate.

Scale introduces another layer of uncertainty. Cell lines selected in plates or small bioreactors must eventually perform under different mixing, oxygen-transfer, nutrient, and waste-product conditions. Product quality is also multidimensional. Titer, aggregation, glycosylation, charge variants, fragmentation, impurity burden, and process robustness may respond differently to the same genetic intervention.

Training data impose practical limits on AI. Industrial cell line data sets are often proprietary, platform specific, and collected under changing experimental conditions. Measurements may differ across laboratories, hosts, vectors, products, and process formats. A model trained on one platform may therefore fail when applied to another without substantial retraining and validation.

The likely outcome is a change in the character of screening rather than its disappearance. Developers may build fewer candidates, but those candidates will still require rigorous comparison. Stability studies, product-quality analysis, process development, and scale-up testing will remain central because design predictions must ultimately be confirmed in the biological and manufacturing contexts that matter.

The discrete technologies described above suggest a future workflow in which cell line development begins with a defined manufacturing phenotype. Developers could specify desired ranges for productivity, growth, stability, impurity burden, glycosylation, and other quality attributes. They could then characterize the molecule’s expected folding, assembly, secretion, and product-quality requirements before selecting an expression and host strategy.

Sequence models could propose promoters, enhancers, untranslated regions, and gene-ratio architectures. A characterized landing pad or epigenomically favorable locus could provide a more controlled genomic context. Host edits could be selected to alter metabolism, secretion, stress responses, apoptosis, or product-quality pathways. Biological reporters and feedback circuits could be added where dynamic control offers an advantage over constitutive intervention.

The first build would not attempt to produce one perfect cell line. It would create a deliberately varied but limited candidate set. High-dimensional phenotypic, imaging, omics, productivity, and quality data could then reveal which design variables mattered and which combinations produced unanticipated tradeoffs. ML could identify patterns among those results, while active learning could prioritize the next candidates expected to improve performance or resolve uncertainty.

No verified study has demonstrated this complete workflow as a unified industrial platform. Its components, however, already exist in recognizable forms: regulatory-sequence design, active experimental selection, targeted integration, multiplex host engineering, metabolic modeling, stress sensing, feedback regulation, glycoengineering, and machine-learning-assisted classification (vide supra).

AI’s most valuable role may therefore be coordination rather than one-step invention. Instead of generating an entire cell line from a single prompt or model, AI could help connect experimental learning across biological layers that are currently optimized separately. Each round of testing would refine both the candidate cell lines and the models used to design the next round.

More deliberate cell-line design could alter how biopharmaceutical developers and contract development and manufacturing organizations (CDMOs) build and use platform knowledge. Characterized genomic loci, modular host edits, regulatory architectures, biological reporters, and product-quality configurations could become reusable platform assets rather than molecule-specific experiments that begin from scratch.

A CDMO with deeply characterized parental hosts and standardized landing pads could compare expression constructs in a more controlled environment. A library of validated host edits could support different manufacturing objectives, while accumulated genotype–phenotype data could improve candidate prioritization across programs. High-throughput testing and machine-learning analysis could help determine which designs deserve the more expensive stages of stability, process, and product-quality evaluation.

The commercial value would depend less on possessing a single “super cell” than on building a learning system. Proprietary data sets linking sequence, locus, genotype, phenotype, process conditions, and product quality could become as important as the physical host platform. The challenge would be learning across client programs while protecting molecule-specific confidential information and accounting for the limited transferability of results from one product to another.

These approaches may eventually support smaller clone panels, earlier alignment between molecule developability and host strategy, more deliberate control of product-quality attributes, and more informative early experiments. Those outcomes remain prospective unless demonstrated directly for a specific platform. Current literature establishes the enabling technologies, not a universal reduction in timelines, costs, or commercial risk.

Production cell lines are not yet designed end to end by AI. What has emerged is a collection of increasingly deliberate capabilities: machine-guided regulatory-sequence design, targeted genomic placement, epigenomically informed locus selection, multiplex host engineering, systems-informed metabolic editing, programmable glycosylation, biological stress sensing, feedback-responsive control, and machine-learning-assisted candidate classification.

The production cell may gradually become less of a biological starting material from which developers search for an exceptional clone and more of a configurable manufacturing platform whose expression program, genomic context, host pathways, stress responses, and product-quality machinery are deliberately specified. Design will not remove the need for screening, characterization, stability testing, or manufacturing-scale validation. Its more realistic promise is to make those experiments smaller in number, more intentional in purpose, and more informative for the next round of engineering.

1. Shi, Jindou, et al. “Accelerating Biopharmaceutical Cell Line Selection with Label-Free Multimodal Nonlinear Optical Microscopy and Machine Learning.” Communications Biology. 8: 157 (2025).

2. Shen, Yuxin, Grzegorz Kudla, and Diego A Oyarzún. “Optimization of Regulatory DNA with Active Learning.” Computational and Structural Biotechnology Journal. 27: 4384–4392 (2025).

3. Friedman, Ryan Z, et al. “Active Learning of Enhancers and Silencers in the Developing Neural Retina.” Cell Systems. 16: 101163 (2025).

4. Gosai, Sager J, et al. “Machine-Guided Design of Cell-Type-Targeting Cis-Regulatory Elements.” Nature. 634: 1211–1220 (2024).

5. Vaknin, Inbal, et al. “A Universal System for Boosting Gene Expression in Eukaryotic Cell-Lines.” Nature Communications. 15: 2394 (2024).

6. Castillo-Hair, Sebastian, et al. “Optimizing 5′UTRs for mRNA-Delivered Gene Editing Using Deep Learning.” Nature Communications. 15: 5284 (2024).

7. Hertel, Oliver, et al. “Enhancing Stability of Recombinant CHO Cells by CRISPR/Cas9-Mediated Site-Specific Integration into Regions with Distinct Histone Modifications.” Frontiers in Bioengineering and Biotechnology. 10: 1010719 (2022).

8. Huhtinen, Olli, et al. “Increased Stable Integration Efficiency in CHO Cells Through Enhanced Nuclear Localization of Bxb1 Serine Integrase.” BMC Biotechnology. 24: 44 (2024).

9. Kol, Stefan, et al. “Multiplex Secretome Engineering Enhances Recombinant Protein Production and Purity.” Nature Communications. 11: 1908 (2020).

10. Shen, Chih-Che, et al. “CRISPR-Cas13d for Gene Knockdown and Engineering of CHO Cells.” ACS Synthetic Biology. 9: 2808–2818 (2020).

11. Ley, Daniel, et al. “Reprogramming Amino Acid Catabolism in CHO Cells with CRISPR-Cas9 Genome Editing Improves Cell Growth and Reduces Byproduct Secretion.” Metabolic Engineering. 56: 120–129 (2019).

12. Kyeong, Minji, and Jae Seong Lee. “Endogenous BiP Reporter System for Simultaneous Identification of ER Stress and Antibody Production in Chinese Hamster Ovary Cells.” Metabolic Engineering. 72: 35–45 (2022).

13. Barrios, Daniela, et al. “Feedback-Responsive Cell Factories for Dynamic Modulation of the Unfolded Protein Response.” Nature Communications. 16: 4106 (2025).

14. Lim, Sheryl Li Yan, et al. “Mammalian Synthetic Gene Circuits for Biopharmaceutical Development & Manufacture.” npj Systems Biology and Applications. 12: 1 (2026).

15. Tian, Weihua, et al. “The Glycosylation Design Space for Recombinant Lysosomal Replacement Enzymes Produced in CHO Cells.” Nature Communications. 10: 1785 (2019).